Cryoport vs PacBio
Cryoport reported revenue of $176 million in fiscal 2025, about the same as PacBio's $160 million in fiscal 2025. Cryoport's revenue grew 12.4% in its latest year, and PacBio's grew 3.9%. Cryoport had an operating margin of -20.9%, against -346.1% at PacBio. Free cash flow was −$25 million at Cryoport and −$114 million at PacBio.
Side by side
| Cryoport | PacBio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $176M | $160M |
| Revenue growth | 12.4% | 3.9% |
| Revenue growth a year, last 5 years | 17.5% | 15.2% |
| Gross margin | 47.1% | 28.6% |
| Operating margin | −20.9% | −346.1% |
| Net margin | 44.4% | −341.5% |
| Free cash flow | −$25M | −$114M |
| Free cash flow margin | −14.2% | −71.2% |
| Return on capital | −23.4% | −77.1% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $10M | $0M |
| Change in diluted share count | 1.5% | 4.0% |
| Last close | $19.89 | $1.96 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 4 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CryoportPacBio
Operating margin
Percent of revenue
CryoportPacBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CryoportPacBio